Nakamura J, Tsujino I, Shima H, Nakaya T, Sugimoto A, Sato T, Watanabe T, Ohira H, Suzuki M, Tsuneta S, Hisada R, Kato M, Konno S.
Clinical and hemodynamic response to imatinib in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis: a pilot study of five cases.
American Journal of Cardiovascular Drugs. in press.
IF= 3.290
Aso K, Kono M, Kanda M, Kudo Y, Sakiyama K, Hisada R, Karino K, Ueda Y, Nakazawa D, Fujieda Y, Kato M, Amengual O and Atsumi T.
Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming.
Nature Commun. in press.
Nomoto H.
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes World J Diabetes
IF：4.560
令和4年度 北海道大学大学院医学研究院 優秀論文賞 阿部 靖矢先生
令和4年度 北海道大学大学院医学研究院 優秀論文賞 狩野 皓平先生
Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka The impact of multi-cultural interfacility video case conference – A novel education model after the COVID pandemic – Journal of the Endocrine Society, in press.
IF：なし
Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.
Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1
study)
Diabetes Obes Metab, in press
IF = 6.408
Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y.
Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study.
Diabetes Ther. 2023 in press
IF = 3.605
Karino K, Kono M, Kanda M, Atsumi T.
Reply.
Arthritis Rheumatol. in press.
IF=15.483
Kato M, Ninagawa K, Atsumi T.
Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study: Reply.
Rheumatology (Oxford). in press
IF=7.046